Replay Webcast Now
Historically, value has flowed to companies that focus on extremes of the value chain. In the pharmaceutical industry, most players are still tightly integrated. A few players, however, have "placed their bets" on the value of innovation, while others are betting at the opposite end of the value chain: on a strong brand and commercial scale.
In this Executive eBriefing, partners in SDG's Life Sciences Practice look at the evolution of the business model in the pharmaceutical industry and the implications it has not only for life sciences players, but also for any sector where industry observers anticipate changes in the business model.
Our speakers contrast the business models choices among industry peers; draw insight on how business model choices impact risk, return, and investment expectations; and assess how this knowledge might influence a company's strategic choices.
Replay Webcast Now